Validation of the <scp>BIOCHIP</scp> test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus

Yang, Anna; Xuan, Rachel; Melbourne, Wei; Tran, Kim; Murrell, Dédée F.

doi:10.1111/jdv.15770

Cited by 32 publications

(21 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, measuring autoantibodies to BP180 and BP230 in the serum is useful for diagnosing BP with high sensitivity (76.1-86.8%) and specificity (85.0-90.5%). 11,12 In this study, the serum of the four patients with available anti-BP180/BP230 data was negative for these autoantibodies, indicating a low probability for BPs.…”

Section: Discussionmentioning

confidence: 53%

Bullous Scabies: Clinical, Dermoscopic, and Pathologic Characteristics of Ten Patients

Jia

Chen

et al. 2021

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

Bullous scabies (BS) is a rare atypical clinical variant of scabies and is easily confused with bullous disorders. The diagnosis of BS is always a challenge, and physicians often misdiagnose BS patients. Patients with BS admitted from 2012 to 2020 were enrolled in this study. The clinical, dermoscopic, and pathological characteristics of the patients were analyzed retrospectively. Ten patients with BS were enrolled in this study. Seven of the 10 patients were male. The bullae were most commonly found on the thighs and arms (80% of patients). Only 30% of patients (3/10) tested positive for mites and/or eggs by the initial skin scraping, but 100% (5/5) of the patients who received dermoscopy tested positive. Among these 10 patients, only five received a skin biopsy. Subepidermal (4/5) and intraepidermal (1/5) bullae with eosinophil and neutrophil infiltration were observed in five patients. Direct immunofluorescence (DIF) indicated linear deposition of IgG in the basement membrane zone in three patients. Physicians should consider the possibility of BS in patients with blisters, pruritus, and poor response to corticosteroids. Dermoscopy should be prioritized for the differential diagnosis of BS to exclude other bullous disorders. Finally, a biopsy should be performed on each patient with bullae.

show abstract

Section: Discussionmentioning

confidence: 53%

Bullous Scabies: Clinical, Dermoscopic, and Pathologic Characteristics of Ten Patients

Jia

Chen

et al. 2021

The American Journal of Tropical Medicine and Hygiene

View full text Add to dashboard Cite

show abstract

“…15 The sensitivity of DSG1 transfected cells on the BIOCHIP has been reported to be between 75 and 90% for pemphigus foliaceous. 8,9 In bullous pemphigoid, the sensitivity of the BP180 mosaic on the BIOCHIP has been found to range more widely between 55.3 and 100%, [8][9][10][11][12]16,17 with a specificity between 96.5 and 100%. [8][9][10][11][12]16,17 This is compared to sensitivities of 45.1-66.7% for the BP230 mosaic on the BIO-CHIP, and a specificity of 39.0-100%.…”

Section: Discussionmentioning

confidence: 99%

“…8,9 In bullous pemphigoid, the sensitivity of the BP180 mosaic on the BIOCHIP has been found to range more widely between 55.3 and 100%, [8][9][10][11][12]16,17 with a specificity between 96.5 and 100%. [8][9][10][11][12]16,17 This is compared to sensitivities of 45.1-66.7% for the BP230 mosaic on the BIO-CHIP, and a specificity of 39.0-100%. [8][9][10][11][12]16,17 The lower sensitivity of the BP230 mosaic compared to the BP180 mosaic is not unexpected given that it is more common to have autoantibodies against BP180, compared to BP230 in bullous pemphigoid.…”

Section: Discussionmentioning

confidence: 99%

Comparison of the EUROIMMUN Dermatology Profile ELISA to the novel BIOCHIP Mosaic 7 for the diagnosis of immunobullous skin disease

Simpson

Scardamaglia

Kok³

et al. 2021

Aust J Dermatology

View full text Add to dashboard Cite

Background:The BIOCHIP is an indirect immunofluorescence diagnostic investigation which identifies multiple autoantibodies with a mosaic panel of target antigen-specific substrates in a single incubation field. The EUROIMMUN Dermatology Profile ELISA allows simultaneous investigation of the six most important autoantibodies in bullous autoimmune dermatoses. Evaluation of the BIOCHIP Mosaic 7, compared to that of the EUROIMMUN Dermatology Profile ELISA, when used as a diagnostic investigation in pemphigus and pemphigoid, was undertaken in an Australian cohort. Methods:The serum of 27 patients was analysed including patients with pemphigus vulgaris (n = 10), pemphigus foliaceous (n = 4), bullous pemphigoid (n = 8), mucous membrane pemphigoid (n = 3) and negative controls (n = 2). Results of the BIOCHIP were compared with the EUROIMMUN Dermatology Profile ELISA, as well as with histology, direct immunofluorescence and indirect immunofluorescence.Results: In pemphigus vulgaris, sensitivity & specificity for the BIOCHIP Mosaic 7 were 100% and 94.1%, comparable to that of the EUROIMMUN Dermatology Profile ELISA with 80% sensitivity and 100% specificity. In bullous pemphigoid, sensitivity of the BIOCHIP was 87.5% and sensitivity of the EUROIMMUN Dermatology ELISA profile was 75%, whilst specificities for both diagnostic methods were 100% in our limited cohort. There was substantial or almost perfect concordance between the BIOCHIP Mosaic 7 and EUROIMMUN Dermatology Profile ELISA for pemphigus vulgaris and bullous pemphigoid. Conclusion:The BIOCHIP Mosaic 7 is a rapid, reliable diagnostic investigation in pemphigus and bullous pemphigoid. Results indicate it is comparable to the EUROIMMUN Dermatology Profile ELISA, whilst also providing additional testing with salt split skin, on one field.

show abstract

“…The method of serological detection of the autoantibodies largely relies on indirect immunofluorescence (IIF) and enzyme-linked immunosorbent assay (ELISA) tests. Recently, novel diagnostic multivariant assays were developed as practical screening tools for patients with suspected ABD with the aim of processing the most common autoantibodies simultaneously [39,40].…”

Section: Serological Studiesmentioning

confidence: 99%

Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment

Lernia

Casanova

Goldust

et al. 2020

Dermatol Pract Concept

View full text Add to dashboard Cite

Autoimmune bullous disorders are a heterogeneous spectrum of skin disorders characterized by the production of autoantibodies against adhesion molecules of the skin. The 2 major groups of diseases are “pemphigus diseases” and “autoimmune bullous diseases of the pemphigoid type.” Pemphigus diseases are a group of autoimmune blistering diseases of the skin and mucous membranes characterized by intraepithelial cleft and acantholysis. The main subtypes of pemphigus include pemphigus vulgaris, pemphigus foliaceus, and paraneoplastic pemphigus. Diagnosis is based on clinical manifestations and confirmed with histological, immunofluorescence, and serological testing. Recently multivariant enzyme‐linked immunosorbent assay systems have been developed as practical screening tools for patients with suspected autoimmune bullous dermatoses. The current first-line treatment of pemphigus is based on systemic corticosteroids that are often combined with immunosuppressive adjuvants, such as azathioprine, mycophenolate mofetil, and the anti-CD20 monoclonal antibody rituximab, usually at initiation of treatment. Rituximab efficacy is higher when it is administered early in the course of the disease. Therefore, it should be used as first-line treatment to improve efficacy and reduce cumulative doses of corticosteroids and their side effects. Treatment of bullous pemphigoid is based on disease extension. Localized and mild forms can be treated with superpotent topical corticosteroids or with nonimmunosuppressive agents. In patients with generalized disease or whose disease is resistant to the treatments described above, systemic corticosteroids are preferred and effective. Adjuvant immunosuppressants are often combined with steroids for their steroid-sparing effect.

show abstract

Validation of the BIOCHIP test for the diagnosis of bullous pemphigoid, pemphigus vulgaris and pemphigus foliaceus

Cited by 32 publications

References 41 publications

Bullous Scabies: Clinical, Dermoscopic, and Pathologic Characteristics of Ten Patients

Bullous Scabies: Clinical, Dermoscopic, and Pathologic Characteristics of Ten Patients

Comparison of the EUROIMMUN Dermatology Profile ELISA to the novel BIOCHIP Mosaic 7 for the diagnosis of immunobullous skin disease

Pemphigus Vulgaris and Bullous Pemphigoid: Update on Diagnosis and Treatment

Contact Info

Product

Resources

About